In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides.
Development of oligonucleotide derivatives as therapeutic agents requires an understanding of their pharmacokinetic behavior. The in vivo disposition and stability of a prototype of such compounds are reported here. The compound studied, a relatively G-rich 38 base 3' phosphopropyl amine oligonucleotide (TFO-1), was cleared from the circulation with a half-life of approximately 10 minutes, displaying distribution kinetics consistent with a two compartment model. TFO-1 was also readily absorbed into circulation from the peritoneal cavity. All tissues examined except brain accumulated the compound reaching concentrations calculated to be in the micromolar range. TFO-1 was found to be stable in circulation and in tissues in that a large fraction of intact material was detected 8 hours after injection, as assessed by gel electrophoresis. Approximately 20-30% of the injected dose was excreted in the urine over an 8 hour period. These results suggest that G-rich oligonucleotides, minimally modified at the 3' end, are relatively stable in vivo and have distribution kinetics favorable to use as therapeutic agents.
Zendegui
J G
JG
Triplex Pharmaceutical Corporation, The Woodlands, TX 77380.
Vasquez
K M
KM
Tinsley
J H
JH
Kessler
D J
DJ
Hogan
M E
ME
D000042:Absorption; D000818:Animals; D001483:Base Sequence; D005260:Female; D007274:Injections, Intraperitoneal; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000493:pharmacokinetics*; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics*; D011437:Propylamines / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D009838:Oligodeoxyribonucleotides; D009943:Organophosphorus Compounds; D011437:Propylamines